Johnson & Johnson: 100 Million Doses Of Vaccine By June For US
The company expects results of its phase 3 trial by next week, and once its vaccine is approved, it would be the third vaccine in the U.S. Sanofi, while awaiting development of its vaccine, says it can help manufacture Pfizer's beginning this summer.
The Hill:
Johnson & Johnson On Track For 100 Million Vaccine Doses By End Of June, Bolstering US Supply
Johnson & Johnson said Tuesday that it is on track to meet its target of 100 million coronavirus vaccine doses for the United States by the end of June, one of a string of confident announcements on vaccine supply. Johnson & Johnson's vaccine trial is being closely watched as it has the potential to produce a third vaccine for the U.S., helping further an increase in available doses. The company said Tuesday that it expects results from its Phase 3 trial “by early next week.” (Sullivan, 1/26)
FiercePharma:
Johnson & Johnson Is 'Comfortable' Meeting Coronavirus Vaccine Delivery Promises, CFO Says
As the world awaits Johnson & Johnson’s phase 3 COVID-19 vaccine data, the company is prepping for regulatory filings and a global rollout. Orders for hundreds of millions of doses are pending. But even as rivals face manufacturing and logistics hurdles, a top J&J exec said his company is “comfortable” meeting its 2021 supply commitments. J&J's one-dose vaccine would provide a major boost to worldwide vaccination efforts as shots from Pfizer/BioNTech, Moderna and AstraZeneca remain in the early stages of their rollouts. News of supply disruptions for the AstraZeneca and Pfizer vaccines has been surfacing in Europe, and U.S. rollouts for the mRNA vaccines have gotten off to a slower-than-expected start. (Sagonowsky, 1/26)
In other news on vaccine manufacturing —
AP:
France's Sanofi To Make Vaccines From Rival Pfizer-BioNTech
French drug maker Sanofi said Wednesday it will help manufacture 125 million doses of the coronavirus vaccine developed by rivals Pfizer and BioNTech, while its own vaccine candidate faces delays. The Germany-based BioNTech will initially produce the vaccines at Sanofi facilities in Frankfurt, starting in the summer, according to a Sanofi statement. The company did not reveal financial details of the agreement. (1/27)
FiercePharma:
Sanofi, After R&D Setback, Lends A Hand To Vaccine Rival Pfizer For Coronavirus Shot Production
Following its midstage coronavirus R&D setback, vaccine giant Sanofi is still looking for ways to help in the world’s effort to beat back the pandemic. It’s teaming up with leading vaccine players Pfizer and BioNTech to produce 100 million doses of the rival vaccine—even as Sanofi works to push its own programs through clinical testing. After Sanofi's weak trial showing in December forced the company to delay its own vaccine development, the French drugmaker approached Pfizer and BioNTech about helping with mRNA shot production, CEO Paul Hudson said in an interview with Le Figaro newspaper. (Sagonowsky, 1/26)
